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Abstract
Objective: We investigated the contribution to sporadic focal epilepsies (FE) of
ultrarare variants in genes coding for the components of complexes regulating
mechanistic Target Of Rapamycin (mTOR)complex 1 (mTORC1). Methods:
We collected genetic data of 121 Italian isolated FE cases and 512 controls by
Whole Exome Sequencing (WES) and single-molecule Molecular Inversion
Probes (smMIPs) targeting 10 genes of the GATOR1, GATOR2, and TSC com-
plexes. We collapsed “qualifying” variants (ultrarare and predicted to be delete-
rious or loss of function) across the examined genes and sought to identify
their enrichment in cases compared to controls. Results: We found eight quali-
fying variants in cases and nine in controls, demonstrating enrichment in FE
patients (P = 0.006; exact unconditional test, one-tailed). Pathogenic variants
were identified in DEPDC5 and TSC2, both major genes for Mendelian FE syn-
dromes. Interpretation: Our findings support the contribution of ultrarare vari-
ants in genes in the mTOR pathway complexes GATOR and TSC to the risk of
sporadic FE and a shared genetic basis between rare and common epilepsies.
The identification of a monogenic etiology in isolated cases, most typically
encountered in clinical practice, may offer to a broader community of patients
the perspective of precision therapies directed by the underlying genetic cause.
Introduction
Epilepsy is a common complex disease with a clear genetic
influence.1 In the last years, next generation sequencing has
proven to be a powerful tool to identify genes underlying rare
Mendelian, well-recognized epilepsy syndromes at an increas-
ingly accelerated pace.2 Conversely, the genetic contribution
to common epilepsies remains still largely unexplored and has
been generally thought oligogenic or polygenic in nature.
Recently, established Mendelian epilepsy genes have been
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
475
demonstrated to be major contributors to common epilep-
sies.3 The risk associated with these genes is mainly attributa-
ble to ultrarare variants (e.g., unseen in the large population
variant databases 1000 genomes, Exome Variant Server [EVS]
and Exome Aggregate Consortium [ExAC]), which is the
same class of variants primarily implicated in the Mendelian
forms. Ultrarare variants of DEPDC5 (DEP domain contain-
ing 5) are responsible for autosomal dominant focal epilep-
sies4 and recently were proposed as risk factors for complex
epilepsies.3 Focal Epilepsies (FE), characterized by seizures
originating within one cerebral hemisphere,5 are the most
common epilepsy form accounting for 60%–70% of all the
epilepsies.6 Familial aggregates typically have no clear-cut pat-
tern of inheritance and, despite reflecting a more frequent
clinical scenario compared to the rare multigenerational epi-
lepsy syndromes, have long been considered poorly informa-
tive for genetic analysis.7 In this genetic continuum where
ultrarare variants span Mendelian and complex inheritance
patterns, sporadic forms of the disease can be in principle
ascribed to variation in established Mendelian genes. DEPDC5
encodes a component of GATOR1 (Gap Activity TOward
Rags 1), a protein complex that like tuberous sclerosis com-
plex (TSC) controls the activity of mTOR complex 1
(mTORC1). Interestingly, the two DEPDC5 GATOR1 partner
genes nitrogen permease regulator-like 2 (NPRL2) and nitro-
gen permease regulator-like 3 (NPRL3) have been recently
identified as novel familial FE genes.8 Mutations in the two
TSC complex subunit genes TSC1/TSC2 are traditionally
linked to tuberous sclerosis, an autosomal dominant multisys-
temic disease characterized by cortical tubers in the brain and
commonly associated with FE.9 It has been demonstrated that
FE-associated mutations in this group of genes cause hyperac-
tivation of mTORC1 signaling, suggesting a common patho-
logical mechanism with important implications for both
patients’ treatment and prognosis.4 However, if considerable
knowledge has been accumulated in the last years about cen-
trality of the mTOR pathway in familial FE, it is far less clear
to what extent its deregulation impacts isolated patients. Here,
we explored the contribution to sporadic, non-lesional FE of
ultrarare variation in genes encoding proteins of the com-
plexes TSC, GATOR1, and GATOR2 (the GATOR1 regulator
complex) (Fig. 1). We also assayed the deregulation of mTOR
pathway in patients carrying pathogenic variants in GATOR1
genes, to evaluate whether the plausible molecular mechanism
underlying disease was visible in patients’ lymphocytes.
Methods
Patient enrollment, collection of control
samples, and study design
Following the approval by the Human Research Ethics Com-
mittee of Bellaria Hospital, Bologna (Prot. N 945/CE; cod
CE: 13084), we enrolled between January 2014 and June 2017
121 Italian sporadic cases (M/F:61/60) diagnosed with non-
acquired FE, according to the following criteria:
 negative family history of epilepsy within the third
degree of kinship;
 no evidence of an epileptogenic lesion on brain MRI,
except for hippocampal sclerosis (HS).
Most patients were diagnosed and followed up in the
Bellaria Hospital of Bologna, while seven cases were
referred by other Italian epilepsy centers through the Ital-
ian league against epilepsy (LICE).
Written informed consent was collected at the time of
recruitment at each clinical site from patients and their
healthy parents, when available.
Diagnosis of FE was based on anatomo-electro-clinical
data collected during clinical assessment and made by agree-
ment among three experts (PT, FB, and LL). Although prior
genetic testing was not required for inclusion in this study,
most patients have had clinically indicated genes examined
in a diagnostic setting. An ad hoc database was created to
collect patients’ data, including age at seizure onset, epilepsy
phenotype, personal history of febrile seizures, intellectual
deficits and psychiatric disorders, focal to bilateral tonic–
clonic seizures and status epilepticus, seizures frequency at
last assessment, antiepileptic treatment and response to
therapy, interictal epileptiform abnormalities, and neu-
roimaging data. All patients underwent targeted neuroradi-
ological study with 1.5 or 3-T brain MRI acquisitions,
following a specific epilepsy protocol.
DNA samples of 431 control subjects (M/F:221/210)
were obtained from the Inter-Department Anti-Smoking
Centre, Modena University Hospital, following the
approval by the Human Research Ethics Committee of
Modena (Prot. N 5554, 03/11/2013). Additionally, in silico
data were collected from WES of 81 subjects (M/F:40/41)
with no manifest neurological conditions enrolled in a
sequencing study on inherited thrombocytopenia approved
by the Ethics Committee of IRCCS San Matteo Hospital,
Pavia (Prot. N 27313-2013).
Sequencing of GATOR/TSC complex genes
and statistical methods
DNA was extracted from peripheral blood of patients and
available parents using the QIAamp DNA Blood Mini Kit
(Qiagen, Venlo, the Netherlands) following the manufac-
turer’s protocol. Genes of GATOR1 (DEPDC5, NPRL2,
NPRL3), GATOR2 (MIOS, SEC13, SEH1L, WDR24,
WDR59), and TSC (TSC1, TSC2) complexes were analyzed.
TBC1D7, the third gene of the TSC complex, was not
included in the gene set since it is linked to an ultrarare auto-
somal recessive macrocephaly/megalencephaly syndrome
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Figure 1. Simplified schematic of GATOR and TSC complexes in the mTOR pathway. The number of qualifying variants identified in each
analyzed gene is reported. Under each gene name, the number of qualifying variants in cases (left) and controls (right), separated by colon.
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without epilepsy.10,11 A customized single-molecule Molec-
ular Inversion Probes (smMIPs) assay12,13 (Data S1) was
designed using MIPgen14 and performed following proto-
cols already described15 on DNA of 508 subjects, 77 FE
patients and 431 Italian controls. Data for the same gene set
were retrieved in silico from 125 Whole Exome Sequencing
(WES) data from 44 FE patients and 81 subjects without
manifest neurological conditions who were included as
additional controls. Raw reads were processed as described
elsewhere.16 Variants (Single Nucleotide Variants [SNVs]
and small insertions/deletions) were called using “Uni-
fiedGenotyper” or “HaplotypeCaller”17 from smMIPs and
WES data, respectively, and variant calls were refined (Data
S1) before being annotated with the Ensembl tool Variant
Effect Predictor (VEP) v.7618 against GENCODE19 canoni-
cal transcripts on reference genome GRCh37 and additional
annotations were obtained by custom scripts. We collected
sequencing coverage statistics across target regions (se-
quence positions within coding exons and canonical splice
sites of the 10 genes) with GATK “Depth of Coverage.”
Principal Component Analysis (PCA) was performed with
EIGENSTRAT20 to check for population structure in cases
and controls (Data S1).
We defined qualifying variants, to be used for collapsing
analysis comparing gene frequencies between FE patients
and controls, as SNVs and small indels not observed in the
ExAC, Exome Variant Server (EVS, http://evs.gs.washing
ton.edu/EVS/), and 1000 genomes databases and for SNVs
only as having a scaled C-score >=15 using Combined
Annotation Dependent Depletion (CADD) v1.3.21 We then
assigned a binary variable to each subject based on absence/
presence, respectively, of any number of qualifying variants
per subject in the gene set. We thus modeled the number of
subjects with at least one variant as a binomial distribution
to identify enrichment of variants in patients compared to
controls. We performed an exact unconditional test22 based
on the score statistic to test the null hypothesis of equality
of proportions of subjects with at least one variant. Data
analyses were performed in R3.4.2 using Package ‘exact2x2’
(https://www.R-project.org/). Based on ExAC data, we cal-
culated the probability of finding a qualifying variant in
any of the 10 genes among controls to be 0.01. If the true
probability among cases ranges between 0.05 and 0.1, we
estimated that the power to identify enrichment in the gene
set with Type I error probability = 0.05 ranges between
0.65 and 0.97.
We classified as pathogenic any qualifying variant in
one of the FE-associated GATOR/TSC genes (DEPDC5,
NPRL2, NPRL3, TSC1, TSC2) if at least one of the follow-
ing criteria was met:
 its predicted impact is loss of function (LOF). As
GATOR1/TSC are negative regulators of mTORC1,
the molecular mechanism underlying epilepsy is
thought to be haploinsufficiency leading to constitu-
tive mTORC1 activation23;
 it had been convincingly associated with FE and/or
epilepsy-related mTORopathies (focal cortical dys-
plasia [FCD], TSC) before.
To understand whether variants previously reported in
FE, irrespective of their frequency in ExAC, were present
in our cohort and could contribute to FE, we searched
through the relevant literature for any variant identified
among cases with ExAC MAF<=0.001.
mTOR pathway activation assay
We assessed the phosphorylation levels of the ribosomal
protein S6 Kinase (S6K) on lymphocytes isolated from
peripheral whole blood samples of patients with variants
identified in a diagnostic setting (patients enrolled in the
present genetic study were not available) and healthy con-
trols (Data S1).
Results
Patient population
All patients had normal brain MRI except five (4.13%) with
HS. Mean age at epilepsy onset (data available for 119
patients) was 16.50  10.33 years (range 3 months to
55 years), mean age at last assessment 36.57  13.63 years,
and mean follow-up time 20.39  12.24 years. Patients’
features are summarized in Table 1.
Data quality checks
We removed 24 samples; all were controls sequenced
by smMIPs which failed to reach required thresholds
for overall on-target sequencing coverage, thus retain-
ing 121 cases and 488 controls for downstream analysis
(Fig. 2).
To exclude spurious differences in the numbers of vari-
ants between the two groups due to sequencing coverage
imbalances, we verified that the mean percentage of on-
target positions for each gene exceeded the required
thresholds in both cases and controls (Table S1). We then
compared the number of rare polymorphic SNVs and
small indels (MAF <= 0.001 in population databases)
between samples sequenced by WES and smMIPs, to
check if merging experimental designs could affect variant
comparisons between cases and controls in this study.
We counted 13 variants in 125 WES (10.4%) and 56 in
484 smMIPs (11.6%) samples, resulting in no apparent
discrepancy between experimental designs (P = 0.71,
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chi-square test). Merging WES and smMIPs data intro-
duced therefore no substantial technological bias.
Finally, we found by PCA that cases and controls clus-
tered together and with TSI (Italians Tuscans) and IBS (Ibe-
rians) 1000 genomes populations, identifying no population
outliers in cases as well as controls. No departure from
HWE was found in SNP genotypes within smMIPs or WES
cohort samples (Table S2).
Enrichment and clinical relevance of
qualifying variants in FE patients
We identified a total of 17 qualifying variants, eight in
patients (6.6%) and nine in controls (1.8%) (Fig. 2),
obtaining evidence for significant variant enrichment in
patients by gene set collapsing analysis (P = 0.006; odds
ratio: 4.25, 95% CI: 1.56–11.56). To validate our analyt-
ical strategy, we inspected the same case–control cohorts
for variants in an independent set of six genes (MTOR,
CNTNAP5, SRGAP3, PIK3CA, RELN, CNTNAP2) to
various degrees implicated in neuropsychiatric distur-
bances including epilepsy. Following the same quality
checks and filtering strategy as for the mTOR pathway
gene set, we counted nine variants in cases (7.4%) and
20 in controls (4%) (Table S3) resulting in no sta-
tistically significant enrichment for variants in cases
(P = 0.10).
Qualifying variants were distributed across 6 of the 10
analyzed genes (Fig. 1). Among FE-associated genes, three
qualifying variants in DEPDC5 and TSC2 are to be classi-
fied as Variants of Unknown Significance (VoUS) while
two variants are pathogenic and as such referenced in the
ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/):
the TSC2 missense substitution p.Arg905Gln (dbSNP ID:
rs45517259; ClinVar ID: RCV000255572.1), already asso-
ciated with clinically mild tuberous sclerosis,24 and the
splice-site change c.193+1G>A (ClinVar ID: RCV00025
4582.1) in DEPDC5, previously described in patients with
Familial Focal Epilepsy with Variable Foci (FFEVF)25,26
(Table 2). Both variants occurred in patients with video-
EEG documented Sleep-related Hypermotor Epilepsy
(SHE), according to the novel diagnostic criteria27 of this
epilepsy syndrome, formerly known as Nocturnal Frontal
Lobe Epilepsy (NFLE).
While qualifying variants were defined as not detected
in ExAC, the gnomAD database (http://gnomad.broadin
stitute.org/) containing a far greater set of exomes and
genomes was released while this work was ongoing. Only
three of the 16 qualifying variants (two in cases and one
in controls) were observed in the gnomAD database, each
with five or less alleles (Table 2), confirming extreme rar-
ity of the whole variant set across human populations
worldwide.
We then manually inspected patients’ data to identify
variants seen in ExAC that were previously reported in
FE patients and found only one case with a DEPDC5
p.Tyr281Phe variant26 (five alleles in ExAC). However,
the same variant was present also in three of our
Table 1. Clinical features of the 121 patients included in the study.
# Patients Valid %
Missing
(%)
Gender
Male 61 50.41 None
Female 60 49.59
Mean age at onset 16.50  10.33 years 2
Brain MRI
Negative 116 95.87 None
HS 5 4.13
Epilepsy type
Temporal 64 52.89 None
Lateral 56 46.28
Mesial 6 4.95
Other 2 1.66
Extra-temporal
(Frontal/insular)
57 47.11
Seizure type
Focal, nonmotor onset 64 52.89 None
Sensory
auditory 49 40.49
cephalic aura 2 1.66
Autonomic
Gastric (rising)
sensation
4 3.30
Cognitive
aphasic 7 5.78
deja vu/jamais vu 2 1.66
Focal, motor onset 57 47.11
hyperkinetic 37 30.58
tonic 20 16.53
Focal to bilateral
tonic–clonic seizures
76 64.41 3 (2.48)
Seizure frequency at last assessment
Daily/multi-daily 16 13.45 2 (1.65)
Weekly 11 9.24
Monthly 15 12.61
Yearly 12 10.08
Sporadic 8 6.71
Absent 57 47.90
Status epilepticus 6 5.04 2 (1.65)
Epileptiform
interictal EEG
64 53.33 1 (0.83)
Drug resistance 47 39.83 3 (2.48)
Personal history
FS 11 9.24 2 (1.65)
ID/borderline IQ 7 5.93 3 (2.48)
Psychiatric disorders 18 15.13 2 (1.65)
Valid: percentage of patients with the feature. Missing: number and
percentage of patients without information for the feature. HS: hip-
pocampal sclerosis.
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controls indicating that it may have MAF in the Italian
population (0.003) substantially higher than in the
European population as represented in ExAC/gnomAD
(7x10-5).
For half patients with qualifying variants, parents’ DNA
was available and had been sequenced by WES allowing
to evaluate the inheritance pattern. One variant (MIOS
p.Ala138Gly) was de novo, while the other three (WDR59
p.Val279Met, DEPDC5 p.Phe1321Leu, and c.193+1G>A)
were inherited. In the patient with the de novo MIOS
event, WES revealed a pathogenic de novo CHRNA4
p.Ser284Leu change, which had been repeatedly reported
in SHE as a hot-spot mutation.28 The MIOS p.Ala138Gly
variant is therefore unlikely to contribute to the patient’s
phenotype.
Evidence of mTORC1 hyperactivation in
lymphocytes of patients with GATOR1
variants
To assay mTORC1 hyperactivation in sporadic or familial
FE patients, we collected fresh blood lymphocytes from
available patients in whom pathogenic variants had been
identified. We tested three predicted LOF changes:
DEPDC5 p.Arg165Tyrfs*14, p.Arg422*, and NPRL3
p.Gln101* (Fig. 3). We observed a significantly increased
expression of S6K and rate of phosphorylated S6K (p-
S6K) in each patient compared to controls. These findings
indicate that mTORC1 hyperactivation is detectable in
cells of patients with sporadic as well as familial FE. As
previously reported for LOF DEPDC5 variants,29 we
Figure 2. Workflow of the case–control gene collapsing analysis.
480 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
mTOR Pathway Genes in Sporadic Focal Epilepsy T. Pippucci et al.
provide evidence that NPRL3 LOF variants impact the
mTOR pathway as well.
Discussion
Few reports have been published on the identification of
mTOR pathway gene variants in large (>100 subjects) col-
lections of sporadic FE patients. These studies were
restricted to DEPDC530,31 or GATOR1 complex genes8
and did not provide estimates of the risk for FE that the
identified variants accounted for.
Here we describe the case–control sequencing strategy
we used to address this shortcoming in the literature, and
we demonstrate that genes of the GATOR/TSC complexes
are collectively enriched for qualifying variants in sporadic
FE patients compared to population-matched controls. In
6.6% of cases versus 1.8% of controls, we identified quali-
fying variants conferring a higher than fourfold risk of
FE.
Even taking into account only those variants considered
as pathogenic according to our stringent criteria, their
percentage in cases (1.7%) is in line with that ascribed to
genes associated with distinctive FE phenotypes in the
respective sporadic forms (LGI1 in epilepsy with auditory
features [EAF]32 or nicotinic acetylcholine receptors
[CHRNA4, CHRNA2, CHRNB2] in SHE).33 This suggests
that the risk ascribable to GATOR/TSC genes is at least as
large as that of major established FE genes.
The pathogenic variants we identified had been before
convincingly associated with FE or related mTORopathies.
The splice-site variant in DEPDC5 has a predicted LOF
impact and therefore also fits with the recognized molec-
ular mechanism of pathogenicity for this gene, which is
haploinsufficiency thought to lead to mTORC1 hyperacti-
vation. This variant resulted to be inherited from a
healthy parent. Similarly, the few sporadic FE patients
previously reported had often inherited the causative vari-
ant,8,30,31 which is congruent with the largely documented
incomplete penetrance in families.8,25,34,35 Unlike severe,
early-onset epilepsies such as epileptic encephalopathies,36
the pathogenic potential of a variant should not be
undervalued in FE based on the fact that it did not occur
de novo. It is rather more relevant that the variant is
ultrarare, as it has been observed that most variants
involved in epilepsy have been seen ever or only once in
ExAC.37
Interestingly, both pathogenic variants were identified
in patients with SHE. The patient with TSC2 p.Arg905Gln
had refractory SHE without evidence of TSC-related white
matter lesions on brain MRI. p.Arg905 is a mutational
hot spot and the same change has been reported in mild
familial and sporadic TSC presenting with hypomelanotic
macules or focal seizures with spontaneous remission or
easily controlled with medication.24,38 We reviewed the
epilepsy phenotypes previously associated with p.Arg9
05Gln among which focal seizures with possible general-
ization was the most frequent seizure type, while only few
patients had prevalent sleep-related events. Thus, we
enlarged the TSC2 p.Arg905Gln mutational spectrum to
non-lesional SHE.
Table 2. Qualifying variants.
Subject type Variant Gene Ex mRNA change AA change CADD CR gnomAD MAF (alleles) Inheritance
Case chr22-32180826-A-G DEPDC5 9 c.A589G p.Asn197Asp 27.1 V - N.A.
Case chr22-32275693-T-C DEPDC5 37 c.T3961C p.Phe1321Leu 25.0 V - Inherited
Case chr22-32156689-G-A DEPDC5 3 c.193+1G>A - 25.9 P - Inherited
Control chr22-32275619-A-T DEPDC5 37 c.A3887T p.His1296Leu 22.8 V - N.A.
Case chr7-7629178-G-A MIOS 9 c.G2027A p.Ser676Asn 26.3 V - N.A.
Case chr7-7612519-C-G MIOS 4 c.C413G p.Ala138Gly 23.7 V - De Novo
Control chr7-7612698-A-G MIOS 4 c.A592G p.Lys198Glu 24.5 V - N.A.
Control chr7-7636048-C-T MIOS 11 c.C2357T p.Ala786Val 34 V - N.A.
Control chr16-136824-C-A NPRL3 14 c.G1587T p.Met529Ile 31 V - N.A.
Control chr16-160550-G-A NPRL3 6 c.C602T p.Ala201Val 28.0 V - N.A.
Case chr16-2124390-A-G TSC2 22 c.A2545G p.Thr849Ala 23.0 V 8.237e-06 (2) N.A.
Case chr16-2126143-G-A TSC2 24 c.G2714A p.Arg905Gln 34 P - N.A.
Control chr16-2114391-C-G TSC2 15 c.C1562G p.Thr521Arg 28.4 V 3.229e-05 (1) N.A.
Control chr16-2122943-G-A TSC2 20 c.G2314A p.Ala772Thr 23.7 V - N.A.
Control chr16-735303-A-G WDR24 7 c.T1973C p.Ile658Thr 24.3 V - N.A.
Control chr16-735306-A-G WDR24 7 c.T1970C p.Leu657Pro 25.6 V - N.A.
Case chr16-74955896-C-T WDR59 10 c.G835A p.Val279Met 34 V 2.031e-05 (5) Inherited
Variants are annotated according to Ensembl transcripts. DEPDC5:ENST00000382112; MIOS: ENST00000340080; NPRL2: ENST00000232501;
NPRL3: ENST00000399953; TSC2: ENST00000219476; WDR24: ENST00000293883; WDR59: ENST00000262144. Ex: Exon C.R.: Clinical Rele-
vance. V: VoUS; P: pathogenic. gnomAD release used is r2.0.2.
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DEPDC5 c.193+1G>A had been identified in affected
members of a FFEVF pedigree showing different patterns
of FE,25,26 including frontal lobe epilepsy, occipital lobe
epilepsy with previous infantile spasms (IS), and severe
multifocal epilepsy with IS, ID, and autistic features.
None of the affected members had SHE.
The occurrence of both pathogenic variants in patients
with SHE raises the question whether GATOR/TSC
Figure 3. Functional assessment of mTORC1 activation in human lymphocytes. (A) List of the evaluated variants; (B) densitometric analysis
of western blot showing the mean ratio of p-S6K over total S6K expression in the tested lymphocytes; (C) representative western blot result.
In panel (B), asterisks indicate significant P-values obtained when comparing patients and controls (two-tailed T-test): **P-value < 0.01,
***P-value < 0.001.
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complex genes may be more likely implicated in specific
FE phenotypes. A relatively higher risk for SHE in partic-
ular is an intriguing hypothesis because of the well-known
association between this group of genes and epilepsy
related to focal cortical dysplasias (FCD), predominantly
manifesting with sleep-related seizures which arise within
the frontal lobe.39 DEPDC5 and TSC2 mutations have been
already reported in sporadic and familial FCD.8,26,40–45
Although the present study was focused on non-lesional FE,
it is still possible that a subtle FCD could not be detected by
conventional brain MRI in the two patients with patho-
genic variants.
Most variants for which GATOR/TSC genes are
enriched in our cases are missense. This suggests that,
together with LOF variants, this class of variation con-
tributes to the risk of FE. However, ultrarare or private
missense variants still pose an important problem for risk
assessment, especially in isolated patients where segrega-
tion data cannot be supportive. Except for TSC2
p.Arg905Gln, all missense variants were indeed classified
as VoUS.
Although adaptation of the ACMG criteria to the speci-
fic situation of GATOR1 variants has proven useful to
increase the accuracy of the clinical classification,46 inter-
pretation of missense variants remains a major challenge.
Our functional data show that mTOR pathway deregu-
lation, as measurable in our ex vivo assay, was similar in
cells of familial and sporadic FE patients carrying a LOF
variant. We also provided evidence that, as for DEPDC5,
also NPRL3-predicted haploinsufficiency was associated
with the plausible molecular mechanism of disease. Func-
tional assessments may be therefore of great help in
reclassifying missense variants in GATOR/TSC genes
based on their effect on mTORC1 activity.29,47 Correct
classification of the variant pathogenic potential is very
important for the clinical use. Drugs targeting the mTOR
pathway, candidate for treating patients with rare familial
mTORopathies, may be effective also in the more com-
mon sporadic FE where the underlying defect is in any of
different genes converging on deregulation of the mTOR
signaling pathway.
Although we retained only variants ever seen in ExAC
in the case–control study, we wanted to understand
whether variants previously reported in FE patients, irre-
spective of their frequency in ExAC, were present also in
our cohort and could contribute to the risk of FE. We
identified only one case with such a variant in DEPDC5
that had been previously reported to segregate in a FE
family.26 The identification of the same variant also in
three of our controls suggests that it has higher frequency
in the Italian population than in ExAC/gnomAD, and
therefore diminishes its potential implication in FE. This
highlights that sequencing control cohorts from local
populations (such as the Italian, not extensively repre-
sented in public variant databases) may also be useful in
reclassifying variants.
From a technical perspective, smMIPs proved to be as
informative as high-coverage WES, highly comparable in
terms of the effectiveness of variant detection. smMIPs
have also been shown to accurately detect variants with
low allelic fraction in the sample.13 Although we identi-
fied no seemingly mosaic variant in our cohorts, it is
possible that sequencing by smMIPS with higher depth of
coverage would help to investigate the role of post-zygo-
tic variants appearing at low fraction in the sequenced
sample.
In conclusion, our findings support the contribution
of ultrarare, likely deleterious variants in genes of the
mTOR pathway regulators GATOR and TSC to the risk
of sporadic, non-lesional FE. Our strategy to collapse
qualifying variants at the level of the gene set, not only
of the single gene, allowed to reveal that a group of
functionally interrelated genes were collectively enriched
for variants in this cohort of sporadic FE patients. We
identified pathogenic variants in major genes responsi-
ble for familial FE demonstrating a shared genetic basis
between rare Mendelian syndromes and the more com-
mon sporadic forms. Most missense changes were clas-
sified as VoUS, and functional assays for the detection
of mTOR pathway hyperactivation may be useful in
discriminating variants with a pathogenic potential from
the presumably benign ones. The identification of a
monogenic etiology in isolated cases, who are the most
typically encountered in the clinical practice, may offer
to a broader community of patients the perspective of
therapies precisely targeted to the underlying genetic
cause.
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